Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results

Reuters

Aug 19

Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results

Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease (MVID), a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1062676) on August 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2560191018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560191018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560191018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560191018","market":"fut","top_or_hot":-1,"title":"Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease (MVID), a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1062676) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease (MVID), a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1062676) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL4MNvNw:1","article_id":"2560191018","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560191018","pubTimestamp":1755608440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results. Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration  to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease , a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition  2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc.","BK4007":"制药"},"translate_title":"Jaguar Health Inc.宣布针对超罕见儿科疾病MVID的Crofelemer进行新的临床研究，初步结果令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Inc. Announces New Clinical Study on Crofelemer for Ultrarare Pediatric Disorder MVID Following Promising Initial Results\n    \n\n        Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease (MVID), a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1062676) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}